Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (3): 408-414    DOI: 10.31083/j.ejgo.2020.03.5312
Original Research Previous articles | Next articles
Sentinel lymph node mapping with carbon nanoparticles in endometrial cancer
J.Y. Chen1, Z.Q. Wang1, S.C. Liang1, H.Y. Hou1, D.B. Chen1, J.L. Wang1()
1Gynecology Department. Peking University people’s Hospital, Beijing, China
Download:  PDF(949KB)  ( 250 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Aim: A retrospective study was conducted to explore the value of sentinel lymph node (SLN) mapping with carbon nanoparticles (CNP) in endometrial cancer patients. Methods: Seventy-six endometrial cancer patients who underwent sentinel lymph node mapping with or without systemic pelvic lymphadenectomy were involved in this study. All patients received cervical injection of carbon nanoparticles. The detection frequency for sentinel lymph nodes was calculated for all 76 patients, while the sensitivity and negative predictive value for metastasis were calculated for patients who underwent additional systemic pelvic lymphadenectomy (n=43). Clinical factors associated with sentinel lymph node detection were also evaluated. Results: The overall and bilateral detection frequencies were 71.1% (54/76) and 61.1% (33/54), respectively. A total of 291 sentinel lymph nodes were removed from 54 patients, with the median number removed per patient being 4 (range 3-7). sentinel lymph nodes were mostly located in the external lilac (45.7%) and obturator (41.2%) regions. Fifteen positive lymph nodes including 6 positive sentinel lymph nodes were found in 5 patients. Two of the five patients failed sentinel lymph node mapping but showed positive lymph nodes after systemic pelvic lymphadenectomy. The sensitivity and negative predictive value of sentinel lymph node mapping were therefore both 100%. Conclusion: The detection frequency of sentinel lymph node mapping with carbon nanoparticles in endometrial cancer patients was not as high as for some other cancer types. However, the accuracy of this method was high despite the relatively low detection frequency. More research is needed to improve sentinel lymph node mapping in endometrial cancer patients.

Key words:  Sentinel lymph node      Endometrial cancer      Carbon nanoparticles     
Submitted:  30 June 2019      Accepted:  19 September 2019      Published:  15 June 2020     
Fund: 2015BAI13B06/National Key Technology Research and Development Program of the Ministry of Science and Technology of China
*Corresponding Author(s):  J.L. Wang     E-mail:  wangjianliu@pku.edu.cn

Cite this article: 

J.Y. Chen, Z.Q. Wang, S.C. Liang, H.Y. Hou, D.B. Chen, J.L. Wang. Sentinel lymph node mapping with carbon nanoparticles in endometrial cancer. European Journal of Gynaecological Oncology, 2020, 41(3): 408-414.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.03.5312     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I3/408

Figure 1.   - The black-stained SLNs with CNP injection (as indicated by the black arrows). a. The CNP-labeled lymph nodes between external and internal lilac artery. b. The CNP-labeled lymph nodes that were resected separately.

Table 1  - Clinical characteristics of patients
Total (n, %)
Pathology type
Atypical hyperplasia 4 (5.3%)
Endometrioid 67 (88.2%)
Mucinous 2 (2.6%)
Serous 2 (2.6%)
Mixed 1 (1.3%)
Grade of endometrioid cancer
1 29 (38.2%)
2 26 (34.2%)
3 12 (15.8%)
FIGO stage
0 [atypical hyperplasia] 4 (5.3%)
I 62 (81.6%)
II 1 (1.3%)
III 8 (10.5%)
IV 1 (1.3%)
LVSI
Present 3 (3.9%)
Absent 73 (96.1%)
Myometrial invasion
< 50% 67 (88.2%)
> 50% 9 (11.8%)
Parametrial involvement
Present 10 (13.2%)
Absent 66 (86.8%)
Surgery (*TLH + BSO +)
SLNB 33 (43.4%)
SLNB + PLND 9 (11.8%)
SLNB + PLND + PALND 34 (44.7%)
Table 2  - Detection rate and accuracy
Detection rate
Overall 71.1% (54/76)
Bilateral 61.1% (33/54)
Unilateral 38.9% (21/54)
Number of SLNs
Total 291.0
Median 4.0 (3.0~7.0)
Number of PLNs
Total 1184.0
Median 27.0 (19.0~35.0)
Number of Positive Nodes
Total 16.0
SLNs 6.0
non-SLNs 10.0
Accuracy PLNs (Cases)
+
SLNs + 3 0
(Cases) 0 25
S 100.0%
NPV 100.0%
Table 3  - The characteristics of the 5 patients with nodal metastasis
Characteristics Case 1 Case 2 Case 3 Case 4 Case 5
Age, y 57 54 64 75 78
Pathology type Endometrioid Endometrioid Endometrioid Serous Serous
Grade 3 3 3 3 3
FIGO stage III III III III IV
LVSI Yes Yes No Yes No
Deep myometrial invasion Yes Yes Yes Yes No
Parametiral involvement No No No No No
SLNB* Yes Yes Yes Yes Yes
PLND* Yes Yes Yes Yes Yes
PALND* Yes No Yes Yes Yes
Number of SLNs 8 0 0 3 4
Number of positive SLNs 2 0 0 1 3
Number of positive non-SLNs 5 2 2 0 0
Table 4  - The distribution of SLNs (Total number = 291.0)
Region Number (n, %)
External iliac 133.0 (45.7)
Obturator 120.0 (41.2)
Common iliac 19.0 (6.5)
Internal lilac 8.0 (2.7)
Inguinal 2.0 (0.7)
sacro anterior 3.0 (1.0)
para-aortic 3.0 (1.0)
inferior vena cava 3.0 (1.0)
Table 5  - The relevant factors might affect the success rate of SLN mapping
Detected Cases (n)
Fail detection
*Detection rate (%) Confidence Intervals (95%) P value
Successful Fail Lower Upper
Pathology Type 0.284 7.804 1.000
Endometriod 47 20 70.1
Non-endometriod 7 2 77.8
FIGO Stage 0.142 2.228 0.462
0 / I 48 18 72.7
II / III / IV 6 4 60.0
BMI* 0.368 2.882 0.956
< 24.0 45 14 76.3
≥ 24.0 9 8 52.9
LVSI* 0.220 4.036 1.000
Present 7 3 70.0
Absent 47 19 71.2
Deep Myometrial Invasion 0.284 7.804 1.000
Present 7 2 77.8
Absent 47 20 70.1
Parametrial Extension 0.992 1.130 0.552
Present 3 0 100.0
Absent 51 22 69.9
Surgical cases 0.396 2.989 0.870
≤ 30 21 9 70.0
>30 33 13 71.7
[1] Wakayama A., Kudaka W., Matsumoto H., Aoyama H., Ooyama T., Taira Y., et al.: “Lymphatic vessel involvement is predictive for lymph node metastasis and an important prognostic factor in endometrial cancer”. Int. J. Clin. Oncol., 2018, 23, 532.
doi: 10.1007/s10147-017-1227-6 pmid: 29275449
[2] Vargas R., Rauh Hain J.A., Clemmer J., Clark R.M., Goodman A., Growdon W.B., et al.: “Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis”. Gynecol. Oncol., 2014, 133, 216.
doi: 10.1016/j.ygyno.2014.02.011
[3] Yost K.J., Cheville A.L., Al Hilli M.M., Mariani A., Barrette B.A., McGree M.E., et al.: “Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life”. Obstet. Gynecol., 2014, 124, 307.
doi: 10.1097/AOG.0000000000000372
[4] Ruscito I., Gasparri M.L., Braicu E.I., Bellati F., Raio L., Sehouli J., et al.: “Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis”. Ann. Surg. Oncol., 2016, 23, 3749.
doi: 10.1245/s10434-016-5236-x pmid: 27160526
[5] NCCN Guidelines Version 2. 2017: “Uterine Neoplasms”. Available at: http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf .
[6] NCCN Guidelines Version 2. 2015: “Uterine Neoplasms”. Available at: http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.
[7] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.
doi: 10.1016/j.ijgo.2009.02.012 pmid: 19367689
[8] Kang S., Yoo H.J., Hwang J.H., Lim M.C., Seo S.S., Park S.Y.: “Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies”. Gynecol. Oncol., 2011, 123, 522.
doi: 10.1016/j.ygyno.2011.08.034
[9] How J.A., O'Farrell P., Amajoud Z., Lau S., Salvador S., How E., et al.: “Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis”. Minerva Ginecol., 2018, 70, 194.
doi: 10.23736/S0026-4784.17.04179-X pmid: 29185673
[10] Geppert B., Lonnerfors C., Bollino M., Arechvo A., Persson J.: “A study on uterine lymphatic anatomy for standardization of pelvic sentinel lymph node detection in endometrial cancer”. Gynecol. Oncol., 2017, 145, 256.
doi: 10.1016/j.ygyno.2017.02.018 pmid: 28196672
[11] Gargiulo T., Giusti M., Bottero A., Leo L., Brokaj L., Armellino F., et al.: “Sentinel Lymph Node (SLN) laparoscopic assessment early stage in endometrial cancer”. Minerva Ginecol., 2003, 55, 259.
pmid: 14581872
[12] Sawicki S., Lass P., Wydra D.: “Sentinel Lymph Node Biopsy in Endometrial Cancer--Comparison of 2 Detection Methods”. Int. J. Gynecol. Cancer, 2015, 25, 1044.
doi: 10.1097/IGC.0000000000000447 pmid: 25853384
[13] Sahbai S., Taran F.A., Fiz F., Staebler A., Becker S., Solomayer E., et al.: “Pericervical Injection of 99mTc-Nanocolloid Is Superior to Peritumoral Injection for Sentinel Lymph Node Detection of Endometrial Cancer in SPECT/CT”. Clin. Nuclear Med., 2016, 41, 927.
doi: 10.1097/RLU.0000000000001414
[14] Abu Rustum N.R., Gomez J.D., Alektiar K.M., Solow R.A., Hensley M.L., Leitao M.M. Jr ., et al.: “The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes”. Gynecol. Oncol., 2009, 115, 236.
doi: 10.1016/j.ygyno.2009.07.016 pmid: 19666190
[15] Papadia A., Zapardiel I., Bussi B., Ghezzi F., Ceccaroni M., De Ponti E., et al.: “Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99(m) with blue dye versus indocyanine green fluorescent dye”. J. Cancer Res.Clinical Oncol, 2017, 143, 475.
[16] Miyashiro I., Hiratsuka M., Sasako M., Sano T., Mizusawa J., Nakamura K., et al.: “High false-negative proportion of intraoperative histological examination as a serious problem for clinical application of sentinel node biopsy for early gastric cancer: final results of the Japan Clinical Oncology Group multicenter trial JCOG0302”. Gastric cancer, 2014, 17, 316.
doi: 10.1007/s10120-013-0285-3
[17] Lu Y., Wei J.Y., Yao D.S., Pan Z.M., Yao Y.: “Application of carbon nanoparticles in laparoscopic sentinel lymph node detection in patients with early-stage cervical cancer”. PLoS One, 2017, 12, e0183834.
doi: 10.1371/journal.pone.0183834 pmid: 28873443
[18] Liang S.C., Wang Z.Q., Wang J.L.: “Clinical analysis of 76 cases of sentinel lymph node detection in cervical cancer and endometrial cancer”. Zhonghua Fu Chan Ke Za Zhi, 2017, 52, 605.
doi: 10.3760/cma.j.issn.0529-567X.2017.09.006 pmid: 28954449
[19] Eitan R., Sabah G., Krissi H., Raban O., Ben Haroush A., Goldschmit C., et al. Robotic blue-dye sentinel lymph node detection for endometrial cancer - Factors predicting successful mapping”. Eur. J. Surg. Oncol., 2015, 41, 1659.
doi: 10.1016/j.ejso.2015.09.006 pmid: 26433709
[20] Colombo N., Preti E., Landoni F., Carinelli S., Colombo A., Marini C., et al.: “Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2013, 24, vi33.
doi: 10.1093/annonc/mdt353 pmid: 24078661
[1] Ikuji Shimazaki, Yasunori Hashiguchi, Makoto Yamauchi, Mari Kasai, Takeshi Fukuda, Tomoyuki Ichimura, Tomoyo Yasui, Toshiyuki Sumi. Secondary small cell vaginal cancer after operative therapy for endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 821-823.
[2] Yu Hui Lim, Sheow Lei Lim, Linda Xiao Hui Lin, Lay Tin Soh, Hoon Seng Khoo Tan, Richard Ming Chert Yeo, Timothy Yong Kuei Lim. Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 705-712.
[3] Eda Kucuktulu, Ahmet Fatih Yurekli. Simultaneous Integrated Intensity Modulated Radiotherapy Boost for Gynecological Cancer when Brachytherapy is not an Option[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 720-725.
[4] Michelle F. Benoit, Kristy K. Ward. Uterine Cancer Normogram to Predict Lymph Node Metastasis: Comparison to the Mayo Algorithm and an External Validation of a Model in a North American Population[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 681-684.
[5] Yusuf Cakmak, Tufan Oge. The effect of age on prediction of concurrent endometrial cancer in patients with atypical endometrial hyperplasia[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 531-535.
[6] Di Wu, Jirui Zhang, Chengxi Yang. Effect of letrozole combined with testosterone on the proliferation and apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 604-608.
[7] B.-H. Zhang, L. Li, J. Ji, J. Guo, X.-L. Zhou, H. Xu, F. Cao, X.-H. Tong. Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 339-342.
[8] J. Feng, J. Wu, M. Zhang, J. Wang, K. Chen, X. Li, J. Xie, J. Zhang, C. Wang. Oleic acid promotes the development of endometrial cancer by up-regulating KLF4 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 432-438.
[9] S. Liu, F. Ruan, M. Shi, Y. Liu, W. Li, B. Bi, H. Wang, W. Lv. Safe fertility-preserving management in a young woman with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 476-479.
[10] E. Kobayashi, M. Kakuda, T. Takiuchi, M. Kodama, M. Shiomi, S. Kakuda, Y. Ueda, K. Sawada, T. Tomimatsu, K. Yoshino, T. Kimura. Indocyanine green is superior to blue colorimetric method for identifying sentinel lymph nodes during laparoscopic surgery for uterine malignancies: a pilot study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 176-180.
[11] K. Plagens–Rotman, M. Piskorz–Szymendera, B. PIĘTA. Lifestyle with particular emphasis on physical activity and genital carcinomas in women[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 233-239.
[12] X.Q. Wang, S.Q. Ma, J.Y. Guo, F. Zhao, X.H. Liang. Characteristics and prognostic factors among premenopausal versus postmenopausal patients with advanced endometrial cancer: a SEER-based analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 1-6.
[13] S. Srdelić Mihalj, V. Čapkun, I. Kuzmić-Prusac. High-grade endometrial cancer survival (endometrioid to non-endometrioid histology comparison)[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 16-22.
[14] Y.-S. Kwon, K. S. Im, S. B. Yoo, W. I. Kim. Two cases of uterus-conserving treatment for early stage endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 145-147.
[15] T. Wada, Y. Hashiguchi, M. Kasai, T. Fukuda, T. Ichimura, T. Yasui, T. Sumi. HMGCR antibody-associated myopathy in patient with endometrial cancer: a rare case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 148-150.
No Suggested Reading articles found!